Insider · CIK 0001860885
Kyri K. Van Hoose
cfoofficer
Files at DRMA (Dermata Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | DRMA Dermata Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Jan 6, 2026 |
| Dec 23, 2025 | DRMA Dermata Therapeutics, Inc. | AGrant or award Common Stock | +122,549 | - | - | 130,423 | Dec 29, 2025 |
| Dec 23, 2025 | DRMA Dermata Therapeutics, Inc. | AGrant or award Series C Warrant (Right to Buy)derivative | +122,549 | - | - | 122,549 | Dec 29, 2025 |
| Dec 23, 2025 | DRMA Dermata Therapeutics, Inc. | AGrant or award Series D Warrant (Right to Buy)derivative | +122,549 | - | - | 122,549 | Dec 29, 2025 |
| Dec 23, 2025 | DRMA Dermata Therapeutics, Inc. | DDisposition to issuer Warrant (Right to Buy)derivative | +7,874 | - | - | 0 | Dec 29, 2025 |
| Dec 23, 2025 | DRMA Dermata Therapeutics, Inc. | AGrant or award Warrant (Right to Buy)derivative | +7,874 | - | - | 7,874 | Dec 29, 2025 |
| Jan 21, 2025 | DRMA Dermata Therapeutics, Inc. | AGrant or award Common Stock | +78,741 | - | - | 78,741 | Jan 23, 2025 |
| Jan 21, 2025 | DRMA Dermata Therapeutics, Inc. | AGrant or award Warrant (Right to Buy)derivative | +78,741 | - | - | 78,741 | Jan 23, 2025 |
| Jan 13, 2025 | DRMA Dermata Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jan 14, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.